# TB-500 Frequently Asked Questions — Thymosin Beta-4 research literature

> Answers to common questions about TB-500 and Thymosin Beta-4: what the fragment is, how it differs from the parent peptide, mechanism, dosing in animal studies, WADA status, half-life, and clinical trial results.

Each answer cites a named study from the references table. The fragment-versus-parent distinction is called out where it matters.

## What is TB-500 and how is it different from Thymosin Beta-4?

TB-500 is a synthetic seven-amino-acid peptide with the sequence `Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH` — that is, residues 17 through 23 of human Thymosin Beta-4 (Tβ4), N-terminally acetylated for stability. Thymosin Beta-4 itself is a 43-amino-acid intracellular peptide encoded by the TMSB4X gene and present in almost every nucleated cell type [1].

The 7-AA TB-500 fragment retains the central `LKKTET` actin-binding motif of the parent peptide but lacks the C-terminal α-helix that crystallography identified as the major determinant of actin sequestration [2], and lacks the N-terminus from which the parent's AcSDKP fragment is cleaved [22]. Essentially every published animal study and every registered human clinical trial of 'Thymosin Beta-4' has used the full 43-AA parent peptide, not the 7-AA fragment [22]. The two terms are routinely conflated in vendor and forum material; the research record does not support that conflation.

## How does TB-500 work at the molecular level?

The proposed mechanism — extrapolated from full-length Tβ4 studies — is built around three actions.

First, actin sequestration: the LKKTET motif binds monomeric G-actin in a 1:1 complex, blocking the actin monomer from joining growing F-actin filaments and maintaining a cellular reservoir of unpolymerized actin for rapid cytoskeletal remodeling [1][2].

Second, signaling: parent Tβ4 binds the PINCH adapter and integrin-linked kinase (ILK) to activate Akt, the cell-survival kinase implicated in cardiomyocyte protection [6]. It also directly binds NF-κB RelA/p65 to block TNF-α-driven inflammatory cytokine transcription [11].

Third, progenitor mobilization: parent Tβ4 reactivates adult epicardial progenitor cells in the heart [7] and chemoattracts skeletal muscle satellite cells [10].

How much of this transfers to the 7-AA fragment is genuinely uncertain — the actin-binding motif is preserved, the signaling and progenitor-mobilization surfaces are mostly missing.

## What does the research say about TB-500 and tissue repair?

The strongest preclinical signal for any Tβ4-class molecule is in cutaneous and corneal wound healing in rodents. Topical 5-microgram dosing accelerated reepithelialization of full-thickness rat punch wounds by 42% at day 4 and 61% at day 7 [3]. The same molecule at the same microgram dose, twice daily topical, accelerated corneal healing and lowered IL-1β and chemokine mRNA after alkali burn in mice [4]. Philp and colleagues then showed both the full peptide and a synthetic peptide containing the actin-binding domain accelerated dermal wound repair in diabetic and aged mice [5].

This last paper is the closest the published literature comes to validating fragment-level wound-healing efficacy. The corneal data anchors the RGN-259 ophthalmic clinical program, which has reached Phase III in two indications [15][16].

## What are typical research doses of TB-500 in animal studies?

Animal studies of Tβ4 cluster around four dose schedules. Topical at 5 micrograms per wound, with or without twice-daily repetition [3][4]. Intraperitoneal at 150 micrograms every three days in adult mice for epicardial mobilization [7]. Intravenous at 3.75 mg per kilogram, single dose, in rats 24 hours after embolic stroke [12]. Intracoronary retroperfusion at the end of ischemia in pigs (route mattered more than dose in this work) [8].

None of these are doses of the 7-AA TB-500 fragment — they are doses of full-length 43-AA Thymosin Beta-4. There is no published rodent dose-finding study for the synthetic heptapeptide [22].

## Is there any human clinical trial data on TB-500 or Thymosin Beta-4?

Yes — but only for the full-length parent peptide.

Two Phase I safety trials have been published. Ruff and colleagues (US, n=40) tested single IV doses of 42 to 1,260 mg, with no dose-limiting toxicities or serious adverse events [13]. Wang and colleagues (China, n=84) tested single IV doses of 0.05 to 25 micrograms per kilogram and multiple doses of 0.5 to 5 micrograms per kilogram daily for ten days, with dose-linear PK and no SAEs [14].

In ophthalmology, the RGN-259 program has reached Phase III in dry eye (ARISE-1/2/3, missed co-primary endpoints with positive secondary signals) [15] and neurotrophic keratopathy (60% versus 12.5% complete healing at day 29; p=0.066) [16]. SEER-3 in European neurotrophic keratitis missed its primary endpoint [22].

In cardiology, RGN-352 (IV Tβ4) reached Phase II in approximately 75 post-MI patients [22].

No human trial has ever been registered or published for the synthetic 7-AA TB-500 fragment.

## What is the half-life of TB-500?

The honest answer: nobody has published a peer-reviewed human pharmacokinetic study of the 7-AA TB-500 heptapeptide. The 'two- to three-hour plasma half-life' figures that circulate online for the fragment trace back to vendor pages and aggregator sites, not primary literature [22].

For full-length recombinant Tβ4, the published human IV pharmacokinetics — established in the Ruff (2010) and Wang (2021) Phase I trials — show biphasic plasma concentration decline with rapid distribution and terminal exposure measured over hours, without dose-dependent accumulation across the tested dose range [13][14]. The N-terminal acetylation in TB-500 plausibly extends solution stability versus the unmodified heptapeptide, but how this translates to in vivo half-life has not been measured in humans [22].

## Is TB-500 banned by WADA?

Yes. TB-500 and Tβ4-class molecules are prohibited at all times under the World Anti-Doping Code, listed under section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and the catch-all S0 (Non-Approved Substances) of the WADA Prohibited List for 2024, 2025, and 2026 [22].

Multiple athlete sanctions and four-year ineligibility periods have been issued under both S0 and S2 in past WADA reporting cycles. Equine doping-control laboratories have validated LC-MS detection of TB-500 in urine and plasma after intravenous administration [20], so the analytical infrastructure to enforce the ban exists in human anti-doping practice as well.

## Is TB-500 FDA-approved?

No. Neither TB-500 nor full-length Thymosin Beta-4 is approved by the FDA — or by the EMA, MHRA, TGA, PMDA, or any other major regulator — for any human indication [22].

RGN-259 (the topical Tβ4 ophthalmic solution) and RGN-352 (the IV Tβ4 formulation) remain investigational drugs. The closest the parent peptide has come to a regulator-grade efficacy result is the Phase III neurotrophic keratopathy trial (NCT02600429), which showed statistically significant complete corneal healing at day 43 in a small population (n=18) [16]. The Phase III dry eye program (ARISE-3, ~700 patients) missed its prespecified co-primary endpoints [15].

## How is TB-500 different from BPC-157?

TB-500 and BPC-157 are unrelated peptides with distinct mechanisms. BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice; its proposed mechanism involves angiogenesis, growth-hormone-receptor upregulation in tendon fibroblasts, and nitric-oxide signaling. TB-500 is a 7-AA fragment of the 43-AA Thymosin Beta-4 protein, with a proposed mechanism centered on G-actin sequestration and the downstream cytoskeletal-remodeling pathways the parent peptide engages [1][6].

They are frequently co-discussed in the underground 'systemic healing' framing because both have rodent musculoskeletal-repair preclinical signals and neither has FDA approval for any human indication. Beyond that shared cultural framing, they share neither sequence, family, nor mechanism.

## What are the risks or concerns with TB-500 research peptides?

The published research record raises several concerns that any reader should weigh.

First, the fragment-versus-parent gap is large: there is no published human PK, efficacy, or safety dataset for the synthetic 7-AA fragment specifically [22].

Second, Tβ4 biology is context-dependent. The same molecule that accelerates dermal, corneal, and cardiac repair appears to be pro-fibrotic in hepatic stellate cells — conditional Tβ4 deletion in those cells reduced liver fibrosis in a mouse CCl4 model [19]. Indiscriminate systemic dosing is not biologically neutral across organs.

Third, Tβ4 promotes angiogenesis and cell migration. Theoretical concerns about effects on occult or pre-existing tumors have been raised in the review literature, although no clinical signal of tumor promotion has been reported in the published safety data to date [22][23].

Fourth, research-chemical TB-500 is sold without GMP manufacturing, lot-release testing, endotoxin control, or sterility assurance. In any unregulated supply chain, the contamination and purity risks frequently dwarf the peptide's pharmacology [22].

## Why is the fragment-versus-parent distinction this important?

Because the public-facing material on TB-500 tends to cite Thymosin Beta-4 papers (Smart 2007 on cardiac progenitor mobilization, Sosne 2002 on corneal healing, Bock-Marquette 2004 on PINCH-ILK-Akt) as if they were TB-500 papers [4][6][7]. They are not. They are studies of the 43-amino-acid parent.

The scientific bridge from parent to fragment is not zero — Philp 2003 explicitly showed wound-healing activity for a synthetic peptide containing the actin-binding domain, comparable to the full peptide [5], and Goldstein and colleagues' 2012 review acknowledges this is a sparse but supportive literature [22]. But it is also not 'the same molecule.' The parent has more interaction surface, releases AcSDKP, and carries more downstream biology. Calling the fragment by the parent's data is a category error that this site is structured to flag at every level.

## Does TB-500 work in humans?

There is no published human efficacy trial of the synthetic 7-AA TB-500 fragment for any indication [22]. There are also no registered Phase II or Phase III trials of the fragment listed on ClinicalTrials.gov [22].

What the human record shows is that full-length recombinant Tβ4 is safe at IV doses up to 1,260 mg single (Ruff 2010) and 25 micrograms per kilogram single (Wang 2021) [13][14]; that 0.1% Tβ4 ophthalmic solution produces statistically significant corneal healing in neurotrophic keratopathy at day 43 [16]; and that the largest dry-eye trial of the same formulation missed its prespecified endpoints [15]. Whether the fragment shares any of this phenotype in humans is, on the published evidence, an open question.

---

An editorial record of the peer-reviewed Thymosin Beta-4 literature — not a clinic, not a vendor, not medical guidance.